Immune Globulin (IG) News

Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises Inc., is pleased to announce that it has again been named a 2022 Pioneer in Performance Measurement by URAC. This marks the second consecutive year that Nufactor has received this prestigious award, having also earned it in 2021.

Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises Inc., is pleased to announce that it has been named a 2021 Pioneer in the URAC Leaders in Performance Measurement (LPM) recognition program.

CND Life Sciences, Inc., an innovative medical technology company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, announced today its national collaboration with NuFactor®, a specialty infusion company and subsidiary of FFF Enterprises, Inc., to educate neurologists on the availability and application of the Syn-One Test™.

These are questions you may have. While it is generally thought everyone should be vaccinated to protect against COVID-19, it is important to consider each person’s medical history and risks. Nufactor recommends consulting with your prescriber to help determine what is best for you.

Heralded as the nation’s leading supplier of critical-care biopharmaceuticals, plasma products and vaccines, FFF Enterprises, Inc., is proud to announce it has earned Certified status for information security by HITRUST.

Nufactor, Inc., a subsidiary of FFF Enterprises, Inc. is pleased to announce that 18 Nufactor pharmacists eligible to take the Immune Globulin National Society’s (IgNS) Ig Certified Pharmacist (IgCP®) have passed the exam.

Nufactor, Inc., a subsidiary of FFF Enterprises, Inc. is pleased to be recognized as the first pharmacy to achieve Ig Certified Pharmacist (IgCP®) credentialing for all of their California pharmacists.

With the coronavirus disease 2019 (COVID-19) on the minds of many Americans, Nufactor recognizes patients may be concerned with their health and have questions regarding the safety of their infusion therapy.

As all of us continue to work together to respond to the rapidly evolving COVID-19 situation, we wanted to take a moment during these uncertain times to share with you our deepest gratitude.

As a culture of caring, we at Nufactor take the health and well-being of our teammates, healthcare professionals and patients very seriously. Each of us plays a vital role in preventing the spread of coronavirus disease 2019 (COVID-19).

Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises, Inc. (FFF) has been selected by Grifols to be included in the limited network of specialty pharmacies for XEMBIFY®

There is a shortage of immunoglobulin (IG), a plasma product used to treat various types of myositis (idiopathic inflammatory myopathy), Myasthenia Gravis (MG), and numerous other autoimmune diseases, and primary – and other – immune deficiencies.

In 2018, as it has over each of the past several years, demand for IG products grew by more than 7 million grams. Collectively, IVIG and subcutaneous IG (SCIG) product shipments last year approached 88 million grams.

Nufactor, a specialty infusion company and subsidiary of FFF Enterprises, Inc. (FFF) has been selected by Octapharma® as one of four limited distribution (LD) pharmacies for Cutaquig®.